Camoteskimab clinical trials
Also written APL-9109 and AEVI-007.
How each study uses camoteskimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the camoteskimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2011 (1)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Apollo Therapeutics Ltd (3) · Avalo Therapeutics, Inc. (1) · MedImmune LLC (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test camoteskimab.
- Oct 2027A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic DermatitisPhase 2 · Apollo Therapeutics Ltd
Studies
Open first, then newest update. How each study uses camoteskimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic DermatitisRecruitingPhase 2Apollo Therapeutics LtdNCT07599813Written as Camoteskimab
- A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic DermatitisCompletedPhase 2Apollo Therapeutics LtdNCT06436183Written as Camoteskimab
- Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple MyelomaCompletedPhase 1Avalo Therapeutics, Inc.NCT04671251Written as AEVI-007
- A Study to Evaluate Camoteskimab in Participants With Still's DiseaseTerminatedPhase 1Apollo Therapeutics LtdNCT04752371Written as Camoteskimab (CERC-007, AVTX-007, AEVI-007)
- A Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedPhase 1MedImmune LLCNCT01322594Written as MEDI2338
Codes
What other systems call camoteskimab · ClinicalTrials.gg INT017488
- UNII (FDA) ONX021SC9OCAMOTESKIMABOne source FDA
- NCI Thesaurus C179215CamoteskimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | ONX021SC9O | CAMOTESKIMAB | One source FDA |
| NCI Thesaurus | C179215 | Camoteskimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.